315 Tautomerase/MIF-like
Ligands and drugs
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
ClassyFire chemical superclasses of the ligands bound by this X-group's proteins, from DrugDomain annotations.
The raw number of superclasses rises with the number of proteins sampled; the per-20 value compares X-groups at equal depth.
| Superclass | Proteins | Expected | 0.25×observed / expected4× | Ratio | Significance |
|---|---|---|---|---|---|
| Homogeneous non-metal compounds | 10 | 5.3 | 1.89× | q = 0.05 | |
| Homogeneous metal compounds | 5 | 12.1 | 0.41× | q = 9.3e-3 | |
| Nucleosides, nucleotides, and analogues | 0 | 6.8 | 0 | q = 1.3e-3 | |
| Phenylpropanoids and polyketides | 4 | 0.5 | 7.80× | not tested | |
| Benzenoids | 5 | 1.8 | 2.77× | not tested | |
| Organic acids and derivatives | 8 | 3.8 | 2.10× | not tested | |
| Organosulfur compounds | 1 | 0.5 | 1.97× | not tested | |
| Mixed metal/non-metal compounds | 1 | 0.5 | 1.93× | not tested | |
| Organoheterocyclic compounds | 5 | 3.8 | 1.32× | not tested | |
| Organic nitrogen compounds | 1 | 0.8 | 1.27× | not tested | |
| Organic oxygen compounds | 3 | 4.9 | 0.61× | not tested | |
| Lipids and lipid-like molecules | 1 | 2.7 | 0.36× | not tested |
Unit: a protein (UniProt accession) with a ligand-binding domain in this X-group, counted once per superclass. Expected counts use each superclass's frequency across all ligand-binding X-groups; significance is Fisher's exact test with Benjamini–Hochberg correction. Buffers and crystallization additives are excluded. ECOD v295.2; the method follows the ECOD 2027 update, whose published figures used a slightly different artifact filter.
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB02175 | MLA | Malonic acid | 12 |
| DB03688 | 3OH | Hydracrylic acid | 12 |
| DB07718 | ENO | 4-Hydroxyphenylpyruvic acid | 8 |
| DB02384 | FHC | (E)-2-Fluoro-P-Hydroxycinnamate | 7 |
| DB09459 | TLA | L-tartaric acid | 6 |
| DB02005 | OXP | 2-Oxo-3-Pentenoic Acid | 5 |
| DB03350 | NCO | Cobalt hexammine ion | 5 |
| DB00695 | FUN | Furosemide | 3 |
| DB01148 | HWL | Flavoxate | 3 |
| DB02375 | MYC | Myricetin | 3 |
| DB02676 | B3P | 2-[3-(2-Hydroxy-1,1-Dihydroxymethyl-Ethylamino)-Propylamino]-2-Hydroxymethyl-Propane-1,3-Diol | 3 |
| DB02728 | YZ9 | 7-Hydroxy-2-Oxo-Chromene-3-Carboxylic Acid Ethyl Ester | 3 |
| DB03297 | PMS | Benzylsulfonic acid | 3 |
| DB07888 | HDI | 3-(4-HYDROXYPHENYL)-4,5-DIHYDRO-5-ISOXAZOLE-ACETIC ACID METHYL ESTER | 3 |
| DB08333 | OX3 | 4-HYDROXYBENZALDEHYDE O-(CYCLOHEXYLCARBONYL)OXIME | 3 |
| DB08334 | OX4 | 3-FLUORO-4-HYDROXYBENZALDEHYDE O-(CYCLOHEXYLCARBONYL)OXIME | 3 |
| DB08335 | OX5 | 4-HYDROXYBENZALDEHYDE O-(3,3-DIMETHYLBUTANOYL)OXIME | 3 |
| DB08765 | ZEC | 6-HYDROXY-1,3-BENZOTHIAZOLE-2-SULFONAMIDE | 3 |
| DB00142 | GLU | Glutamic acid | 2 |
| DB01880 | DHC | 3,4-Dihydroxycinnamic Acid | 2 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| CL | CHLORIDE ION | 103 |
| NAmetal | SODIUM ION | 30 |
| 7DH | (3E)-5-hydroxy-2-oxopent-3-enoic acid | 17 |
| 6Y5 | 5-fluoranyl-2-oxidanylidene-pentanoic acid | 15 |
| 3OH | 3-HYDROXY-PROPANOIC ACID | 14 |
| 3TX | 4-[4-(quinolin-2-yl)-1H-1,2,3-triazol-1-yl]phenol | 12 |
| ENO | 3-(4-HYDROXY-PHENYL)PYRUVIC ACID | 12 |
| MLA | MALONIC ACID | 12 |
| PR6 | 3-chloro-3-oxopropanoic acid | 10 |
| RW1 | 4-phenylpyrimidine | 10 |
| A1BXY | prop-2-ynoic acid | 9 |
| EN1 | (2E)-2-hydroxy-3-(4-hydroxyphenyl)prop-2-enoic acid | 9 |
| ZNmetal | ZINC ION | 8 |
| A1AWY | 3-bromo-3-oxopropanoic acid | 7 |
| FHC | 2-FLUORO-3-(4-HYDROXYPHENYL)-2E-PROPENEOATE | 7 |
| 9BE | N-benzylthioformamide | 6 |
| A1IZH | (1~{Z},2~{S})-1-[(~{E})-3-(2-hydroxyphenyl)prop-2-enylidene]-1$l^{4}-azolidine-2-carbaldehyde | 6 |
| AVR | (2R)-2-amino-1-[2-(1-methylethyl)pyrazolo[1,5-a]pyridin-3-yl]propan-1-one | 6 |
| LE2 | N-(2-phenylethyl)thioformamide | 6 |
| TLA | L(+)-TARTARIC ACID | 6 |